Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) is advancing a novel approach to cancer therapy that could address significant unmet needs in oncology. In a recent interview on the BioMedWire Podcast, Chief Medical Officer Dr. Islam Mohamed discussed the company's lead drug candidate, ONC010, which targets the DNA repair enzyme polynucleotide kinase phosphatase (PNKP). This target represents a new frontier in the DNA damage response pathway, and ONC010's unique dual-selectivity mechanisms may offer a safer and more effective treatment option for patients with certain genetic mutations.
Mohamed explained that ONC010 employs synthetic lethality to selectively kill cancer cells that have lost PTEN or SHP-1, two tumor suppressor proteins. This approach aims to minimize harm to healthy cells, potentially reducing side effects commonly associated with traditional chemotherapies. Additionally, ONC010 uses nanoparticle delivery to concentrate the drug within tumor tissue, further enhancing its selectivity and potency. Preclinical research conducted at the University of Alberta demonstrated that the nano-formulated PNKP inhibitor exhibited single-agent antitumor activity, was well-tolerated at tested doses, and significantly prolonged survival compared to controls. These findings provide a strong rationale for advancing ONC010 into first-in-human clinical trials.
The implications of this announcement are substantial for the biotechnology and oncology sectors. Onco-Innovations holds an exclusive worldwide license to patented technology directed at therapeutic inhibition of PNKP, positioning the company as a leader in this emerging field. If successful in clinical trials, ONC010 could become a first-in-class treatment for cancers characterized by PTEN or SHP-1 deficiencies, which include various aggressive tumor types. The dual-selectivity strategy may also reduce the risk of off-target toxicity, a common challenge in cancer drug development. For investors, the progress of ONC010 represents a potential value driver, as positive clinical results could lead to partnerships or licensing deals with larger pharmaceutical companies. The company's focus on a novel target like PNKP differentiates it from competitors and addresses a critical gap in cancer therapy.
To view the full press release and learn more about Onco-Innovations' plans for ONC010, visit https://ibn.fm/XgpMR. The latest news and updates relating to ONNVF are available in the company's newsroom at https://ibn.fm/ONNVF. For more information about BioMedWire, please visit https://www.BioMedWire.com. Full terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.
As Onco-Innovations prepares for its first-in-human clinical program, the oncology community will be watching closely. The success of ONC010 could validate PNKP as a viable target and open new avenues for precision medicine. With its innovative mechanisms and strong preclinical data, Onco-Innovations is well-positioned to make a meaningful impact in the fight against cancer.
